Search

Displaying results 4871 - 4880 of 10000 in total
  1. Drug

    Roxifiban

    go.drugbank.com/drugs/DB21089
    Experimental

    Roxifiban has a monoisotopic molecular weight of 447.21 Da. … The usage of the INN stem '-fiban' in the name indicates that Roxifiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).

  2. Drug

    Sibrafiban

    go.drugbank.com/drugs/DB21420
    Experimental

    Sibrafiban has a monoisotopic molecular weight of 420.2 Da. … The usage of the INN stem '-fiban' in the name indicates that Sibrafiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).

  3. Drug

    Zerencotrep

    go.drugbank.com/drugs/DB21710
    Experimental

    Zerencotrep has a monoisotopic molecular weight of 524.11 Da. … The usage of the INN stem '-cotrep' in the name indicates that Zerencotrep is a transient receptor potential canonical channel 5 (TRPC5) antagonist.

  4. Drug

    Vicasinabin

    go.drugbank.com/drugs/DB21587
    Investigational

    Vicasinabin has a monoisotopic molecular weight of 358.2 Da. … Vicasinabin is under investigation in clinical trial NCT04265261 (A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic

  5. Drug

    3-hydroxyanthranilic acid

    go.drugbank.com/drugs/DB03644
    Experimental

    An oxidation product of tryptophan metabolism. It may be a free radical scavenger and a carcinogen.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    MKC1106-PP

    go.drugbank.com/drugs/DB06030
    Experimental

    MKC1106-PP is a 3-component investigational vaccine made up of a DNA plasmid (pPRA-PSM) and 2 peptides E-PRA and E-PSM. … MKC1106-PP was under investigation in clinical trial NCT00423254 (Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.).

  7. Drug

    LV-SMENP Vaccine

    go.drugbank.com/drugs/DB15804
    Experimental

    are based on domains of selected viral proteins. … LV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which

  8. Drug

    Lamifiban

    go.drugbank.com/drugs/DB20451
    Experimental

    Lamifiban has a monoisotopic molecular weight of 468.2 Da. … The usage of the INN stem '-fiban' in the name indicates that Lamifiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).

  9. Drug

    Lotrafiban

    go.drugbank.com/drugs/DB20872
    Experimental

    Lotrafiban has a monoisotopic molecular weight of 428.24 Da. … The usage of the INN stem '-fiban' in the name indicates that Lotrafiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).

  10. Drug

    Masofaniten

    go.drugbank.com/drugs/DB21580
    Investigational

    Masofaniten has a monoisotopic molecular weight of 534.09 Da. … Masofaniten is under investigation in clinical trial NCT06312670 (Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer).